Sahajanand Medical Technologies Q2 FY27 earnings call: SMT reported Q2 FY27 revenue growth of 24.7% year-on-year to INR 373 crores, with EBITDA...
Results · Finvezto · 5 Nov 2026 · Sahajanand Medical Technologies (SMT)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 373 | - | - |
| Operating profit | 65 | - | - |
| Net profit | 26 | - | - |
| Operating margin | 17.4% | - | - |
| Net margin | 7.0% | - | - |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- Sahajanand Medical Technologies Q2 FY27 earnings call: SMT reported Q2 FY27 revenue growth of 24.7% year-on-year to INR 373 crores, with EBITDA rising 36.6% to INR 65 crores and PAT up 26.6% to INR 26... Source
- SMT reported Q2 FY27 revenue growth of 24.7% year-on-year to INR 373 crores, with EBITDA rising 36.6% to INR 65 crores and PAT up 26.6% to INR 26 crores. Earnings call
- H1 FY27 gross margin contracted 170 basis points year-on-year to 74.3%, primarily due to faster growth in lower-margin traded products and higher input and labor costs. Earnings call
- Operating leverage drove Q2 FY27 EBITDA margin expansion of 154 basis points to 17.6% as employee costs and other expenses decreased as a percentage of revenue. Earnings call
What to watch
- Management on capex: All in all, the guidance of capex is around INR70 crores for FY 2027 and FY 2028 as well.
- Management on ebitda margin: So by FY 2029, you will see the EBITDA margin of company somewhere around 20%.
Links
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.